TY - JOUR T1 - Differential Expression of Hypoxia-Inducible Protein 2 Among Different Histological Types of Epithelial Ovarian Cancer and in Clear Cell Adenocarcinomas JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 220-226 LP - 220-226 DO - 10.1111/IGC.0b013e3181ca1e16 VL - 20 IS - 2 AU - Sadako Nishimura AU - Hiroshi Tsuda AU - Kiyoshi Ito AU - Masashi Takano AU - Yoshito Terai AU - Toshiko Jobo AU - Junzo Kigawa AU - Toru Sugiyama AU - Nobuo Yaegashi AU - Daisuke Aoki Y1 - 2010/02/01 UR - http://ijgc.bmj.com/content/20/2/220-226.abstract N2 - Objectives: Epithelial ovarian cancer (EOC) can be classified into 5 major histological types. Among them, clear cell adenocarcinoma (CCC) has a poor response to chemotherapy and poor prognosis compared with other histological types. Previously, we reported that the hypoxia-inducible protein 2 (HIG2) gene might be a new biomarker for CCCs, based on its expression profile. In this study, we generated a polyclonal antiserum to HIG2 to explore the use of HIG2 as a predictive biomarker in EOC. In addition, HIG2 expression was evaluated in uterine endometrial and renal CCCs.Methods: Hypoxia-inducible protein 2 expression was analyzed by immunohistochemistry in formalin-fixed surgical samples from 254 EOC, 17 endometrial, and 29 renal CCC patients.Results: Hypoxia-inducible protein 2 is expressed in 175 of 254 ovarian cancer cases. Cytoplasmic HIG2 expression is significantly more frequent in ovarian CCC (83.1%) than in serous (54.9%, P = 0.0001), mucinous (40%, P = 0.00002), or endometrioid (58.1%, P = 0.003) adenocarcinoma. The chemoresponse rate was higher in 24 ovarian CCC patients with cytoplasmic HIG2 expression than in 6 CCC patients without HIG2 expression (62.5% [15/24] vs 0% [0/6], P = 0.02). In contrast, there was no relationship between nuclear HIG2 expression and chemoresponse. Cytoplasmic and nuclear HIG2 expressions are significantly more frequent in ovarian and uterine than renal CCC (P = 0.04).Conclusions: Hypoxia-inducible protein 2 may be used as a marker for early detection of ovarian CCCs or for prediction of response to chemotherapy, but HIG2 expression does not predict survival of patients with CCC. ER -